Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biovet JSCLTS:0III Debt-to-EBITDA is 1.41 as of Dec. 2016, which is 61% below its 10-year median of 3.66. The stock has 1 warning sign investors should review.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Biovet JSC's Debt-to-EBITDA or its related term are showing as below:
LTS:0III'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.86 Med: 3.66 Max: 13.93
Current: 1.86
During the past 8 years, the highest Debt-to-EBITDA Ratio of Biovet JSC was 13.93. The lowest was 1.86. And the median was 3.66.
LTS:0III's Debt-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.63
vs LTS:0III: 1.86
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Biovet JSC Debt-to-EBITDA Related Terms
Biovet JSC Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Biovet JSC's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0III vs ADMP, AGRX, BUDZ: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biovet JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biovet JSC Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biovet JSC's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biovet JSC's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2016) EBITDA data.
Biovet JSC (LTS:0III) has a Debt-to-EBITDA of 1.41 as of Dec. 2016. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Biovet JSC. This is 61% below median its historical median of 3.66. Over the past decade, Biovet JSC's Debt-to-EBITDA has ranged from 1.86 to 13.93.
Is Biovet JSC's Debt-to-EBITDA too high?
Biovet JSC's current Debt-to-EBITDA of 1.41 is 61% below median its 10-year median of 3.66. Over the past 10 years, this metric has ranged from a low of 1.86 to a high of 13.93. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Biovet JSC's value of 1.41 is 13.5% below this industry median.
How does Biovet JSC's Debt-to-EBITDA compare to ADMP and AGRX?
Biovet JSC's Debt-to-EBITDA of 1.41 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.63. Biovet JSC's value of 1.41 is 13.5% below this benchmark. Historically, Biovet JSC's own Debt-to-EBITDA has ranged from 1.86 to 13.93 over the past decade. While the company's 10-year median is 3.66 vs. the industry median of 1.63, Biovet JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biovet JSC's current Debt-to-EBITDA of 1.41 is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Biovet JSC. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biovet JSC's current Debt-to-EBITDA is 1.41, which is 61% below median its own 10-year median of 3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current Debt-to-EBITDA of 1.41. The current Debt-to-EBITDA is 1.41, which is 61% below median its 10-year median of 3.66 and 13.5% below the Drug Manufacturers industry median of 1.63. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current Debt-to-EBITDA is 1.41 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0III has been successfully added to your 
